bioRxivMicrobiology
Atypical molecular basis for drug resistance to mitochondrial function inhibitors in Plasmodium falciparum
H. J. Painter, J. M. Morrisey, M. W. Mather, L. M. Orchard, C. Luck, M. J. Smilkstein, M. K. Riscoe, A. B. Vaidya, M. Llinas
Abstract
The continued emergence of drug-resistant Plasmodium falciparum parasites hinders global attempts to eradicate malaria, emphasizing the need to identify new antimalarial drugs. Attractive targets for chemotherapeutic intervention are the cytochrome (cyt) bc1 complex, which is an essential component of the mitochondrial electron transport chain (mtETC) necessary for ubiquinone recycling and mitochondrially localized dihydroorotate dehydrogenase (DHODH) critical for de novo pyrimidine synthesis. Despite the essentiality of this complex, resistance to a novel acridone class of compounds targeting cyt bc1 was readily attained, resulting in a parasite strain (SB1-A6) that was pan-resistant to both mtETC and DHODH inhibitors. Here we describe the molecular mechanism behind the resistance of the SB1-A6 parasite line which lacks the common cyt bc1 point mutations characteristic of resistance to mtETC inhibitors. Using Illumina whole-genome sequencing, we have identified both a copy number variation ([~]2x) and a single-nucleotide polymorphism (C276F) associated with pfdhodh in SB1-A6. We have characterized the role of both genetic lesions by mimicking the copy number variation via episomal expression of pfdhodh and introducing the identified SNP using CRISPR/Cas9 and assessed their contributions to drug resistance. Although both of these genetic polymorphisms have been previously identified as contributing to both DSM-1 (1) and atovaquone resistance (2, 3), SB1-A6 represents a unique genotype in which both alterations are present in a single line, suggesting that the combination contributes to the pan-resistant phenotype. This novel mechanism of resistance to mtETC inhibition has critical implications for the development of future drugs targeting the bc1 complex or de novo pyrimidine synthesis that could help guide future anti-malarial combination therapies and reduce the rapid development of drug resistance in the field.
- organism: plant (other)
- assay: whole-genome sequencing
- research focus: drug response / drug discovery
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mitochondrial heteroplasmy is responsible for Atovaquone drug resistance in Plasmodium falciparum
Sasha Siegel, Andrea Rivero, … Dennis E. Kyle·bioRxiv·Dec 10, 2017
- Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum is dispensable and not the functional target of putative NDH2 quinolone inhibitors
H. Ke, S. M. Ganesan, … A. B. Vaidya·bioRxiv·Oct 5, 2018
- Plasmodium falciparum quinine resistance is multifactorial and includes a role for the drug/metabolite transporters PfCRT and DMT1
Mariko Kanai, Sachel Mok, … David A. Fidock·bioRxiv·Sep 27, 2024
- Genetic ablation of the mitochondrial ribosome in Plasmodium falciparum sensitizes the human malaria parasite to antimalarial drugs targeting mitochondrial functions
- A histone methyltransferase inhibitor can reverse epigenetically acquired drug resistance in the malaria parasite Plasmodium falciparum
A. Chan, A. Dziedziech, … J. Ankarklev·bioRxiv·Sep 19, 2019
- Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum
K. Kumpornsin, T. Kochakarn, … M. C. Lee·bioRxiv·Aug 23, 2022